| pubmed-article:8832001 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8832001 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8832001 | lifeskim:mentions | umls-concept:C0003308 | lld:lifeskim |
| pubmed-article:8832001 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:8832001 | lifeskim:mentions | umls-concept:C1442162 | lld:lifeskim |
| pubmed-article:8832001 | lifeskim:mentions | umls-concept:C1831743 | lld:lifeskim |
| pubmed-article:8832001 | lifeskim:mentions | umls-concept:C1328050 | lld:lifeskim |
| pubmed-article:8832001 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:8832001 | lifeskim:mentions | umls-concept:C1550718 | lld:lifeskim |
| pubmed-article:8832001 | lifeskim:mentions | umls-concept:C1514923 | lld:lifeskim |
| pubmed-article:8832001 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8832001 | pubmed:dateCreated | 1997-2-27 | lld:pubmed |
| pubmed-article:8832001 | pubmed:abstractText | Systemic fungal infections (SFI) in patients receiving high-dose chemotherapy (HDC) are a frequent cause of morbidity and mortality. Preclinical studies have reported augmented antifungal activity of monocytes, macrophage cells, and neutrophils exposed to certain colony-stimulating factors (CSF), including GM-CSF. We conducted a retrospective descriptive epidemiologic study to examine the characteristics of 145 consecutive patients receiving HDC administered with or without autologous stem cell transplantation (ASCT) and who subsequently received either GM-CSF and G-CSF, G-CSF alone, GM-CSF +/- IL-3 or no CSF. The analysis of this patient population sought to define the incidence of SFI and its relationship to therapy with monocyte/macrophage-stimulating (MMS group) cytokines (GM-CSF and G-CSF; GM-CSF +/- IL-3) or to cytokines which do not result in monocyte/macrophage stimulation (NMMS group, G-CSF alone or no CSF). Risk factors for the development of SFI were balanced between the MMS (n = 70) and NMMS (n = 75) groups. Two patients (2.9%) in the MMS and nine patients (12%) in the NMMS groups developed SFI. The risk ratio for developing SFI in the NMMS group compared to the MMS group was 4.20 (P = 0.023). This relationship was confounded, however, by the diagnosis of hematologic tumor or solid tumor (RR = 3.15, P = 0.082). SFI was the primary cause or major contributing factor in five of the 10 total deaths in our study population. Four SFI-related deaths occurred in the NMMS group and one SFI-related death occurred in the MMS group. Our data suggest a protective role for GM-CSF, IL-3 or other MMS cytokines in preventing SFI in patients receiving HDC. This should be further investigated as a potential complementary approach to conventional strategies in antifungal prophylaxis for patients receiving HDC. | lld:pubmed |
| pubmed-article:8832001 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8832001 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8832001 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8832001 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8832001 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8832001 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8832001 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8832001 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8832001 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:8832001 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:8832001 | pubmed:author | pubmed-author:SpitzerGG | lld:pubmed |
| pubmed-article:8832001 | pubmed:author | pubmed-author:NiemeyerRR | lld:pubmed |
| pubmed-article:8832001 | pubmed:author | pubmed-author:HarrisonB RBR | lld:pubmed |
| pubmed-article:8832001 | pubmed:author | pubmed-author:McIntyreWW | lld:pubmed |
| pubmed-article:8832001 | pubmed:author | pubmed-author:DunphyF RFR | lld:pubmed |
| pubmed-article:8832001 | pubmed:author | pubmed-author:VelasquezW... | lld:pubmed |
| pubmed-article:8832001 | pubmed:author | pubmed-author:PetruskaP JPJ | lld:pubmed |
| pubmed-article:8832001 | pubmed:author | pubmed-author:VrahnosDD | lld:pubmed |
| pubmed-article:8832001 | pubmed:author | pubmed-author:AdkinsD RDR | lld:pubmed |
| pubmed-article:8832001 | pubmed:author | pubmed-author:BowersC ECE | lld:pubmed |
| pubmed-article:8832001 | pubmed:author | pubmed-author:PetersB GBG | lld:pubmed |
| pubmed-article:8832001 | pubmed:author | pubmed-author:AuberryS ESE | lld:pubmed |
| pubmed-article:8832001 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8832001 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:8832001 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8832001 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8832001 | pubmed:pagination | 93-102 | lld:pubmed |
| pubmed-article:8832001 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:meshHeading | pubmed-meshheading:8832001-... | lld:pubmed |
| pubmed-article:8832001 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8832001 | pubmed:articleTitle | Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis. | lld:pubmed |
| pubmed-article:8832001 | pubmed:affiliation | Department of Pharmacy, Saint Louis University Hospital, MO 63110-0250, USA. | lld:pubmed |
| pubmed-article:8832001 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8832001 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:8832001 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8832001 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8832001 | lld:pubmed |
